OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sklar on the Role of Nivolumab in Bladder Cancer

January 10th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the role of nivolumab in the treatment of patients with bladder cancer.

Dr. Swanson on Surgical Choices for Multifocal Lung Cancer

January 10th 2017

Scott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses surgical choices for patients with multifocal lung cancer.

Dr. Bueno on Gene Expression Signatures for Squamous Cell Lung Carcinoma

January 10th 2017

Raphael Bueno, MD, chief, Division of Thoracic Surgery co-director, Brigham and Women’s Lung Center, vice chairman of Surgery for Cancer and Translational Research, professor at Harvard Medical School, discusses gene expression signatures for squamous cell lung carcinoma.

Nab-Paclitaxel as Neoadjuvant Therapy for Breast Cancer

January 10th 2017

Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy of breast cancer.

Dr. Kosari on Antitumor Immunity in Small Cell Lung Cancer

January 10th 2017

Farhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses anti-tumor immunity as a key determinant for small-cell lung cancer (SCLC) survivorship.

Dr. Kristeleit on the Efficacy of Rucaparib in Ovarian Cancer

January 10th 2017

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the efficacy of rucaparib in the treatment of patients with ovarian cancer.

Dr. Stein on Trials Investigating Biomarkers in Prostate Cancer

January 9th 2017

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses trials investigating the use of circulating tumor cells as biomarkers for patients with prostate cancer.

Dr. Hassan on Immunotherapy in Malignant Pleural Mesothelioma

January 9th 2017

Raffit Hassan, MD, head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute Center for Cancer Research discusses immunotherapy in malignant pleural mesothelioma.

Dr. Birrer on Prevalence of Cervical Cancer in the United States

January 9th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the prevalence of cervical cancer in the United States.

Dr. Montero Discusses PERTAIN Study in HER2-Positive Breast Cancer

January 9th 2017

Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.

Dr. Venook on Advice for Oncologists Treating Patients With CRC

January 9th 2017

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, provides advice to community oncologists who are treating patients with colorectal cancer.

Dr. O'Regan Discusses BELLE-3 Study in Breast Cancer

January 7th 2017

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment and were treated with an aromatase inhibitor.

Dr. Coleman on Findings From the AZURE Trial for Breast Cancer Treatment

January 7th 2017

Robert E. Coleman, MBBS, MD, FRCP, FRCPE, professor of Medical Oncology and head of the Academic Unit of Clinical Oncology at the University of Sheffield, discusses the safety findings from the 10-year follow-up of the adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer, which was studied in the AZURE trial.

Dr. Hammers on Nivolumab/Ipilimumab Data in RCC

January 7th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses a mature data set regarding nivolumab and ipilimumab in the treatment of patients with renal cell carcinoma.

Dr. Herbst on the Impact of Frontline Immunotherapy in Lung Cancer

January 7th 2017

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the impact that immunotherapy has had on the frontline treatment of patients with lung cancer.

Dr. Bunn on Current Role of Precision Medicine for Lung Cancer

January 6th 2017

Paul A. Bunn, Jr, MD, professor of Medicine in Medical Oncology and head of the Division of Medical Oncology at the University of Colorado, discusses the current role of precision medicine in lung cancer.

Dr. Girard on Maximizing Outcomes of Lung Cancer Treatments

January 6th 2017

Nicolas Girard, MD, professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the Thoracic Oncology Service of the Hospices Civils de Lyon, discusses the optimal methods to maximize the outcomes of crizitonib (Xalkori) when used as a treatment for patients with non-small cell lung cancer (NSCLC).

Steven Buechler Discusses EarlyR Gene Signature in the BIG 1-98 Trial for Breast Cancer

January 6th 2017

Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group (BIG) 1-98 study. This randomized, double-blind, phase III trial compared letrozole with tamoxifen as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

Dr. Muggia on Challenges in Ovarian Cancer Treatment

January 6th 2017

Franco M. Muggia, MD, professor, Department of Medicine, NYU Langone Medical Center, discusses the current challenges oncologists are facing in the treatment landscape of ovarian cancer.

Dr. Landgren on Questions After POLLUX and CASTOR Studies in Myeloma

January 6th 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses unanswered questions following the results of the phase III POLLUX and CASTOR studies, which explored the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone, respectively.